Three dimensional conformal radiotherapy in patients with T2a-b, N0, M0 prostatic carcinoma.
The current study was undertaken to evaluate the Prostate Specific Antigen (PSA) relapse free survival and the prognostic factors in a total of 38 patients with stages of T2a-b, N0, M0 prostate carcinoma treated with three-dimensional conformal radiotherapy (3D-CRT). Mean 69.63 Gy was given with 3D-CRT, the mean follow up time was 13.89 months, and the mean prebiopsied PSA level was 25.12 ng/ml. The 2-year PSA relapse free survival was 47.37% for the entire group. The 2-year PSA relapse free survival rates were 100% and 44.74% for the patients with Gleason score < or = 7 and greater than 7 (p < or = 0.05). Patients with prebiopsied PSA level < or = 10 ng/ml and the stages of T2a or T2b did not show any significant differences (p > or = 0.05). Although the few case number and short term follow up, in this study 3D-CRT was a new effective technique to prostate cancer for our institutes and the Gleason score was important predictor of PSA relapse free survival.
Ankara University Medical Faculty, Department of Radiation Oncology, Cebeci Hospital, Turkey. kurtman@dialup.ankara.edi.tr
C
C
Kurtman
B
B
Celebioğlu
O
O
Göğüş
M N
MN
Andrieu
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011878:Radiotherapy / Q000379:methods; D015996:Survival Rate